前收市價 | 0.1000 |
開市 | 0.1000 |
買盤 | 0.0000 |
賣出價 | 1.0000 |
拍板 | 12.50 |
到期日 | 2024-05-17 |
今日波幅 | 0.1000 - 0.1000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 17 |
The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.